Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2018
Pharmacy Choice - News - Over-the-Counter Drugs - January 20, 2018

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 37     Next >>     Go To Page:

1/20/18 - Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial
BOULDER, Colo. and CASTRES, France, Jan. 20, 2018/ PRNewswire/ Array BioPharma Inc. and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients
1/20/18 - Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Exelixis, Inc. today announced the presentation of updated results from the Genentech- sponsored phase 1 b clinical trial of cobimetinib, an Exelixis- discovered MEK inhibitor, in combination with atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer.
1/20/18 - Study Results from City University of New York Broaden Understanding of Wellness [Limited output transcranial electrical stimulation (LOTES-2017):...
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Current study results on Wellness have been published. According to news reporting originating in New York City, New York, by NewsRx journalists, research stated, "We present device standards for low-power non-invasive electrical brain stimulation devices classified as limite
1/19/18 - Drug Rescue Market: Challenges and Opportunities Report 2024
Albany, NY 01/19/2018 Drug rescue is also termed as rescue medicines. These are given only when needed or in emergency cases. Drug which is given to counter or block the effect of other medicines are called as rescue medicines.
1/19/18 - Move faster to make life-saving cure for opioid abuse more easily available
In a recent Senate confirmation hearing for the role of secretary of Health and Human Services, nominee Alex Azar mentioned fighting the scourge of the opioid epidemic as one of four priorities that would guide him as head of the department.. They should have asked if he thinks the Food and Drug Administration should reschedule naloxone as
1/19/18 - Sens. Isakson, Casey Introduce Bipartisan Legislation to Reform Over-the-Counter Drug Regulation
Johnny Isakson, R- Georgia, issued the following news release:. U.S. Senator Johnny Isakson, R- Ga., and Bob Casey, D- Pa., introduced bipartisan legislation yesterday that would overhaul the way over-the-counter medications are regulated and brought to market. The current system used by the Food and Drug Administration to regulate these medication
1/19/18 - Tabuk Pharmaceuticals Signs an Exclusive Licensing and Supply Agreement with red otc development GmbH
Tabuk Pharmaceuticals Manufacturing Company, one of the leading pharmaceutical companies in the Middle East and North Africa region, has entered into an exclusive licensing and supply agreement with red otc development GmbH on Ivy oro-dispersible thin films, red otc is a leading German company that creates and develops innovative and highly competi
1/18/18 - Bausch + Lomb Receives FDA Approval of Lumify - The Only Over-The-Counter (OTC) Eye Drop With Low-Dose Brimonidine for the Treatment of Ocular Redness
Bausch+ Lomb, a leading global eye health company, announced that the U.S. Food and Drug Administration has approved LUMIFY (TM) as the first and only over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness. "We are proud to offer this unique new OTC eye drop to help our physicians and their patie
1/18/18 - Bausch + Lomb Receives FDA Approval of LUMIFY - The Only Over-The-Counter Eye Drop with Low-Dose Brimonidine for the Treatment of Ocular Redness
BRIDGEWATER, New Jersey- Bausch+ Lomb, a leading global eye health company, announced that the U.S. Food and Drug Administration has approved LUMIFY as the first and only over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness. 'We are proud to offer this unique new OTC eye drop to help our physici
1/18/18 - Fosun-Backed Biopharma Firms Value Now Tops $1.55 Billion [Arab Finance (Egypt)]
A Fosun- backed biopharmaceutical developer waiting to list on the Chinese mainland now has a value of 10 billion yuan, crossing an important threshold that could make it eligible to seek a listing in the more-liquid Hong Kong market. Shanghai Henlius Biotech Inc. reached the latest milestone after having raised $190 million, according to Shenzhen
1/18/18 - Innovus Pharma Announces Official Launch of its Amazon, Walmart, eBay and Wish On-Line Stores with a Combined 116 Product SKUs
Innovus Pharmaceuticals, Inc., an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men s and women s health and vitality and respiratory diseases, today announced the...
1/18/18 - Innovus Pharma Hemorrhoid Drug Xyralid Receives Approval in Canada
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced the approval of its Product License Application in Canada for its lidocaine-based cream...
1/18/18 - Novartis Granted US FDA Priority Review for Kymriah (Tisagenlecleucel), Formerly CTL019, for Adults With R/r DLBCL
If approved by the FDA and EMA, Kymriah would represent the first chimeric antigen receptor T cell therapy available for two distinct indications in non-Hodgkin lymphoma and B-cell ALL. Kymriah became the first CAR-T cell therapy to receive regulatory approval when it was approved by the FDA in August 2017 for the treatment of patients up to 25 yea
1/18/18 - Novartis granted US FDA Priority Review for Kymriah formerly CTL019 for adults with r/r DLBCL
If approved by the FDA and EMA, Kymriah would represent the first chimeric antigen receptor T cell therapy available for two distinct indications in non-Hodgkin lymphoma and B-cell ALL. Kymriah became the first CAR-T cell therapy to receive regulatory approval when it was approved by the FDA in August 2017 for the treatment of patients up to 25 yea
1/18/18 - Nutra Pharma Partners with EuroAmerican IP to Distribute Nyloxin for Sale to Government Agencies
via OTC PR WIRE Nutra Pharma Corporation, a biotechnology company marketing Nyloxin and Pet Pain-Away? in the over-the-counter pain management market, announced today that they have partnered with EuroAmerican IP, LLC to distribute their Over-the-Counter pain reliever, Nyloxin Topical Gel, through the Federal Supply Schedule. The succ
1/18/18 - Sen. Isakson, Johnny - (R - GA) News Release
WASHINGTON- U.S. Senator Johnny Isakson, R- Ga., and Bob Casey, D- Pa., introduced bipartisan legislation yesterday that would overhaul the way over-the-counter medications are regulated and brought to market. The current system used by the Food and Drug Administration to regulate these medications, called the "over-the-counter monograph system," w
1/18/18 - Singapore Pharmaceutical Market 2017: Key Players Novartis International AG, Abbot Laboratories , Roche Holding AG , Melbourne Drugs and More
WiseGuyReports published new report, titled "Singapore Pharmaceutical Market" Market Overview Development of new medicines which can prevent and treat all incurable diseases is the main focus of global pharmaceutical ind...
1/17/18 - Active Pharma Ingredient (API) Market To Boom Globally Due To Growing Occurrence of Cancer, Technological Innovations & Rapid Industrialization Till 2022 | Million Insights
According to new report available with Million Insights, Active Pharma Ingredient market report on is foretold to provide a robust support for industry players to lay a solid foundation for their business growth. It includes a comprehensive evaluation of the market's growth status and market risk. Furthermore, it provides detail market variables, t
1/17/18 - Civilian Health and Medical Program of the Department of Veterans Affairs
SUMMARY: The Department of Veterans Affairs proposes to amend its regulations governing the Civilian Health and Medical Program of the Department of Veterans Affairs. ADDRESSES: Written comments may be submitted through http://www.Regulations.gov; by mail or hand-delivery to the Director, Regulation and Policy Management, Department of Veterans...
1/17/18 - GNW-News: Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL (english)
*Filing acceptance marks second Priority Review granted to Kymriah by the FDA. for two distinct indications, underscoring the potential of first ever FDA-. *Novartis is working closely with the FDA and EMA to make Kymriah available.
1/17/18 - Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
*Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA- approved CAR-T therapy* EMA granted accelerated assessment to Kymriah for children, young adults with r/r B-cell ALL and adults with r/r DLBCL who are ineligible for autologous stem cell transplan
1/17/18 - Novartis granted US FDA Priority Review for Kymriah? (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
If approved by the FDA and EMA, Kymriah would represent the first chimeric antigen receptor T cell therapy available for two distinct indications in non-Hodgkin lymphoma and B-cell ALL. Kymriah became the first CAR-T cell therapy to receive regulatory approval when it was approved by the FDA in August 2017 for the treatment of patients up to 25 yea
1/17/18 - Rep. Guthrie Legislation Approved by Health Subcommittee
Today, the House Energy and Commerce Committee's Subcommittee on Health voted for and approved the Pharmaceutical Information Exchange Act, introduced by Congressman Brett Guthrie, vice chair of the subcommittee, as well as the Over-the-Counter Monograph Safety, Innovation, and Reform Act, which Congressman Guthrie cosponsored. This communication w
1/17/18 - Rep. S. Brett Guthrie (R-KY) News Release
WASHINGTON, D.C.- Today, the House Energy and Commerce Committee's Subcommittee on Health voted for and approved the Pharmaceutical Information Exchange Act, introduced by Congressman Brett Guthrie, vice chair of the subcommittee, as well as the Over-the-Counter Monograph Safety, Innovation, and Reform Act, which Congressman Guthrie cosponsored.
1/16/18 - Concerning dietary supplements
As a Nutritionist Dietary Technician Registered and a certified healthcare professional I was distressed to read the column by Ms. Bunton concerning the use of various supplements. However, unlike prescription medications dietary supplements do not undergo any rigorous testing by the FDA. The Food and Drug Administration does not test supplements f
Articles(s): 1 - 25 of 37     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415